TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00034138
Drug: oregovomab
Normalized name: Oregovomab
DrugBank: Oregovomab (DB04964)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01653717
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg/m2 by vein on Days -5 to Day -3.
Study: NCT01918202
Drug: 20 mg PF-02545920
Normalized name: cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subject will receive a single dose of 20 mg PF-02545920.
Study: NCT01918202
Drug: PF-02545920
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose will be selected based on the results obtained for Cohort 1. Dose options range from 30 mg to 10 mg, 5 mg, 2mg, 1 mg.~This cohort is optional.
Study: NCT01918202
Drug: PF-02545920
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose will be selected based on the results obtained for Cohort 1 and cohort 2.
Study: NCT02759393
Drug: Dexlansoprazole
Normalized name: Dexlansoprazole
DrugBank: Dexlansoprazole (DB05351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: receiving 8-week PPI
Study: NCT02759393
Drug: Lansoprazole
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: receiving 8-week PPI
Study: NCT00001940
Drug: Voriconazole
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01971489
Drug: Buparlisib
Normalized name: Buparlisib
DrugBank: Buparlisib (DB11666)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT01971489
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01971489
Drug: Gemcitabine Hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02559180
Drug: aflibercept
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: aflibercept 2mg given intravitreally every month until resolution of fluid in retina and then continued every 2 months for a total of 24 months of treatment
Study: NCT00446485
Drug: Ginkgo biloba standardized extract 24/6
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets, 120 mg/day (60 mg two times daily) during 6 months
Study: NCT02422797
Drug: CAR
Normalized name: Icar
DrugBank: Nicardipine (DB00622)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CAR included the following combinations: 2 NRTIs + 1 INI, 2 NRTIs + 1 NNRTI, or 2 NRTIs + 1 PI.
Study: NCT01833663
Drug: Solifenacin Succinate Tablets
Normalized name: Solifenacin Succinate Tablets
DrugBank: Solifenacin (DB01591)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01833663
Drug: Estrogen
Normalized name: Estrogen
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00446485
Drug: Ginkgo Biloba standardized extract 24/6
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets, 60 mg/day during 6 months
Study: NCT00991926
Drug: Orlistat
Normalized name: Orlistat
DrugBank: Orlistat (DB01083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: orlistat (Xenical, Roche, UK)120 mg tid
Study: NCT01367301
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT01367301
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00003577
Drug: epirubicin hydrochloride
Normalized name: Epirubicin Hydrochloride
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04821193
Drug: Skin antisepsis with 5% NaHCO3 water solution
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-vitro analysis of the solutions was done first. Then solutions were applied, and peripheric intravenous catheter was installed
Study: NCT04821193
Drug: Skin antisepsis with 2% Chlorhexidine Gluconate solution
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In-vitro analysis of the solutions was done first. Then solutions were applied, and peripheric intravenous catheter was installed
Study: NCT01767948
Drug: PCI-32765
Normalized name: PCI-27483
DrugBank: PCI-27483 (DB13000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCI-32765 140 mg will be administered as a single dose, orally, on Day 1.
Study: NCT02965586
Drug: intrathecal
Normalized name: Lioresal Intrathecal
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intrathecal block will be performed in sitting position using 25 G spinal needle at either the L3-L4 or L4-L5 intervertebral spaces.
Study: NCT02535286
Drug: Umbralisib
Normalized name: Umbralisib
DrugBank: Umbralisib (DB14989)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A once daily oral agent
Study: NCT04543890
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide will be administered IV 100mg/m2 on days 1-3, 22-24, 43-45 and 64-66.
Study: NCT04543890
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin will be administered IV 80mg/m2 on days 1, 22, 43 and 64.
Study: NCT04648423
Drug: Sodium Oxybate
Normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: solution for oral administration
Study: NCT01528007
Drug: Naltrexone pharmacotherapy
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naltrexone 50mg when graving to gamble.
Study: NCT04409314
Drug: Fluorine F 18-fluoroazomycin Arabinoside
Normalized name: Fluoroazomycin arabinoside F-18
DrugBank: Fluoroazomycin arabinoside F-18 (DB15134)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT00409201
Drug: reboxetine adjuvant therapy
Normalized name: REBOXETINE
DrugBank: Reboxetine (DB00234)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04495881
Drug: Sitagliptin 100mg
Normalized name: Sitagliptin 100mg Oral tablet
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sitagliptin 100mg Qd
Study: NCT04225910
Drug: 225Ac-PSMA
Normalized name: 68Ga-Psma-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: all the patients will receive 225Ac-PSMA RLT for 2 cycles. The dosage will be calculated according to 100KBq/kg body weight. The drug will be administered by vein injection.
Study: NCT03138655
Drug: Vedolizumab
Normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Vedolizumab IV infusion.
Study: NCT00606164
Drug: Bryostatin for Injection
Normalized name: Bryostatin 1
DrugBank: Bryostatin 1 (DB11752)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single one-hour intravenous infusion of 10 or 15 ug/m2 Bryostatin for Injection on Day 1
Study: NCT00535405
Drug: Atorvastatin 10 mg
Normalized name: atorvastatin 10 MG
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin 10 mg and Placebo for ezetimibe and placebo for simvastatin once daily for 12 weeks
Study: NCT00535405
Drug: Atorvastatin 20 mg
Normalized name: atorvastatin 20 MG
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin 20 mg and Placebo for ezetimibe and placebo for simvastatin once daily for 12 weeks
Study: NCT00535405
Drug: Atorvastatin 40 mg
Normalized name: atorvastatin 40 MG
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin 40 mg and Placebo for ezetimibe and placebo for simvastatin once daily for 12 weeks
Study: NCT02108600
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Will receive tocilizumab 8 mg/kg intravenously at four-week intervals for a total of 6 doses. In addition, will continue usual immunosuppressive regimen.
Study: NCT05211011
Drug: Fosfomycin
Normalized name: FOSFOMYCIN
DrugBank: Fosfomycin (DB00828)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infectofos 5 g
Study: NCT04116476
Drug: MT-7117
Normalized name: lipase
DrugBank: Pancrelipase (DB00085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Dose of MT-7117
Study: NCT03704441
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bupivacaine dose
Study: NCT00950079
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 mL/kg for 1 hour immediately before contrast injection , 1mg/kg/hr during procedure and 6 hours after procedure
Study: NCT00950079
Drug: saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.9% normal saline with 1 mL/kg/hr infusion 12 hours before procedure and 12 hours after procedure
Study: NCT01496430
Drug: Azilsartan medoxomil
Normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03096223
Drug: KHK4083
Normalized name: Anti-CD134 human monoclonal antibody (IgG1, KHK4083 dimer)
DrugBank: Rocatinlimab (DB18809)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV administration
Study: NCT02509598
Drug: Tc99m tilmanocept
Normalized name: technetium (99mTc) tilmanocept
DrugBank: Tilmanocept (DB15373)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of 0.5 mCi and 50 ug of Tc99m tilmanocept administered intradermally, peritumorally approximately 15 minutes to 8 hours before surgery
Study: NCT00932152
Drug: fulvestrant (Faslodex)
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fulvestrant (Faslodex) IM 250 mg monthly after a loading dose of 500 mg on day 1 and 250 mg on day 15 of cycle 1.
Study: NCT00932152
Drug: anastrozole (Arimidex)
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anastrozole (Arimidex) 1 mg orally QD
Study: NCT00932152
Drug: Bevacizumab (Avastin)
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab (Avastin) 15 mg/kg IV, every 21 days
Study: NCT03591679
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 units by slow intravenous drip injection
Study: NCT00421343
Drug: alendronate with cholecalciferol
Normalized name: alendronate / cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: alendronate 70mg /cholecalciferol 2800IU orally once weekly
Study: NCT03151304
Drug: Pracinostat
Normalized name: Pracinostat
DrugBank: Pracinostat (DB05223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 mg capsule
Study: NCT03151304
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: SC or IV injection
Study: NCT00598572
Drug: Deferoxamine Mesylate
Normalized name: Deferoxamine Mesylate
DrugBank: Deferoxamine (DB00746)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Various dose-regimens ranging from 7 mg/kg to 125 mg/kg (with a maximum allowable total daily dose of 6000 mg at any of the tested dose tiers, regardless of patient's weight), administered daily by IV infusion for three consecutive days.
Study: NCT03311750
Drug: Panitumumab
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 6 mg/Kg will be administered intravenous over 1 hour on Day 1 every 2 weeks or 9 mg/Kg every 3 weeks.
Study: NCT00655343
Drug: ATG-Fresenius S
Normalized name: ATG-Fresenius S
DrugBank: ATG-Fresenius S (DB05320)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg rabbit immunoglobulin (IgG) in 1 ml of sterile solution~20 mg/kg body weight per day diluted in 500 ml physiological saline, slow intravenous infusion at days -3, -2, -1 prior to transplantation
Study: NCT00564330
Drug: Esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20mg bid
Study: NCT03277924
Drug: Sunitinib 37.5 MG, Sunitinib 25 MG [Sutent]
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
Study: NCT03277924
Drug: Nivolumab 100 MG/10 ML [Opdivo]
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
Study: NCT03277924
Drug: Epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
Study: NCT03277924
Drug: Ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
Study: NCT03277924
Drug: Dacarbazine
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
Study: NCT03277924
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
Study: NCT02122692
Drug: Lu AE58054 30 mg
Normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lu AE58054 encapsulated film-coated tablets, once daily, Day 1-5, orally
Study: NCT02122692
Drug: Lu AE58054 30 mg + itraconazole 200 mg
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lu AE58054 encapsulated film-coated tablets, once daily, Day 6-11, orally + itraconazole capsules, once daily, Day 6-11, orally
Study: NCT02122692
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole capsules, once daily, Day 12-13, orally
Study: NCT00464789
Drug: Bazedoxifene/Conjugated Estrogens 20 mg/0.625 mg tablet
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02889523
Drug: Tazemetostat
Normalized name: tazemetostat
DrugBank: Tazemetostat (DB12887)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablets 200 mg, to be administrated per os
Study: NCT02889523
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 375 mg/m²/dose, D1
Study: NCT02889523
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.4 mg/m²/dose (max 2 mg), D1
Study: NCT00547560
Drug: GSI-953
Normalized name: GSI-136
DrugBank: GSI-136 (DB12819)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule, 10- and 50-mg, either once a day for 14 days or twice a day for 14 days, depending on cohort assignment.
Study: NCT00360243
Drug: flibanserin
Normalized name: Flibanserin
DrugBank: Flibanserin (DB04908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Experimental: flibanserin 25 mg b.i.d
Study: NCT00360243
Drug: flibanserin
Normalized name: Flibanserin
DrugBank: Flibanserin (DB04908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Experimental: flibanserin 50mg qhs
Study: NCT00360243
Drug: flibanserin
Normalized name: Flibanserin
DrugBank: Flibanserin (DB04908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Experimental: flibanserin 50mg b.i.d.
Study: NCT02217319
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anaesthesia is induced (1-2 mg/kg) and maintained (5-7 mg/kg/h) with propofol and remifentanil (1 µg/kg and 0,2-0,4 µg/kg/min). After induction of anesthesia the propofol infusion is stopped and patients receive 1 MAC Sevoflurane over 30 min. Then the propofol infusion is restarted and Sevoflurane is washed out.
Study: NCT02217319
Drug: TIVA
Normalized name: Ultiva
DrugBank: Platelet Activating Factor (DB02261)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anaesthesia is induced (1-2 mg/kg) and maintained (5-7 mg/kg/h) with propofol and remifentanil (1 µg/kg and 0,2-0,4 µg/kg/min).
Study: NCT03471767
Drug: AXS-05
Normalized name: AX
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dextromethorphan Immediate Release + Bupropion Sustained Release: Take 1 tablet two times per day, at least 8 hours apart and 1 hour prior to a meal, and 2 hours after a meal.
Study: NCT03471767
Drug: Bupropion SR
Normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion Sustained Release: Take 1 tablet two times per day, at least 8 hours apart and 1 hour prior to a meal, and 2 hours after a meal.
Study: NCT00121303
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00121303
Drug: daunorubicin hydrochloride
Normalized name: Daunorubicin Hydrochloride
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00121303
Drug: gemtuzumab ozogamicin
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00657852
Drug: Disodium pamidronate
Normalized name: Disodium pamidronate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of 90 mg disodium pamidronate within days 7-12 and at 3 months after liver transplantation, diluted in 500 ml of 5% glucose serum and administered as a 4-hour continuous intravenous infusion
Study: NCT01151579
Drug: Levalbuterol
Normalized name: Levalbuterol
DrugBank: Levosalbutamol (DB13139)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: inhaled Levalbuterol 0.625 mg inhaled Levalbuterol 2.5 mg
Study: NCT01151579
Drug: Albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized albuterol 2.5mg
Study: NCT01471730
Drug: Fibrinogen
Normalized name: fibrinogen
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All the patients randomized and not withdrawn will be tested 20 minutes before removal of aortic cross clamping with a Thromboelastometric fibrinogen test FIBTEM (Rotem) . They will all receive either human fibrinogen concentrate (according to the formula: (22 \[mm\] - MCF \[mm\]) \* body weight \[kg\] / 140 \[m\] = whole g fibrinogen to be dosed as HFC) (treatment group) or placebo (control group). Study drug or placebo has to be administered after protamine.
Study: NCT01471730
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Normal saline will be administered to control patients.
Study: NCT01471730
Drug: Prothrombin complex
Normalized name: prothrombin complex
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After 15min from study drug administration and in presence of ongoing microvascular bleeding, we run a CT EXTEM. In case of prolonged CT time at EXTEM as long as 80 seconds \[M1\] , they will receive coagulation factors concentrates (Confidex) at a weight-based dose of 7 U/kg b.w. (treatment group) or placebo.
Study: NCT00898573
Drug: lapatinib ditosylate
Normalized name: Lapatinib Ditosylate
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04167592
Drug: Benzydamine Hydrochloride 0.15% Oral Rinse
DrugBank: Benzydamine (DB09084)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzydamine Hydrochloride 0.15% Oral Rinse was used to gargle prior to Endoscopic Retrograde Cholangiopancreatography (ERCP) procedure.
Study: NCT04167592
Drug: Water
Normalized name: Water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water was used to gargle prior to Endoscopic Retrograde Cholangiopancreatography (ERCP) procedure.
Study: NCT00791544
Drug: AVE1642
Normalized name: Anti-cd122 monoclonal antibody ave1642
DrugBank: Veligrotug (DB18976)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous infusion
Study: NCT02042495
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04263337
Drug: [18F] Flortaucipir
DrugBank: Flortaucipir (DB15033)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Per study protocol static PET images will be acquired after IV infusion of F-T807 to generate standard uptake values (SUVs). PET imaging is necessary in order to address the primary and secondary outcome measures as a component of neurological health (i.e., presence of proteinopathies empirically associated with neurodegenerative disease, cognitive decline, and neurological signs/symptoms). All groups will participate in this portion of the protocol.
Study: NCT00660504
Drug: Amrubicin Hydrochloride
Normalized name: Valrubicin
DrugBank: Amrubicin (DB06263)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amrubicin Hydrochloride combined with cisplatin
Study: NCT00660504
Drug: Etoposide-Cisplatin combined chemotherapy
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: combined chemotherapy
Study: NCT00791544
Drug: sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral intake
Study: NCT00791544
Drug: erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral intake
Study: NCT00534404
Drug: Nicotine patches
Normalized name: NICOTINE 7 mg in 1 g TRANSDERMAL PATCH [Sielkin QUIT SMOKING NICOTINE PATCHES]
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will wear nicotine patches.
Study: NCT01019668
Drug: Verteporfin PDT, half-dose
DrugBank: Verteporfin (DB00460)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: half the regular dose or half the regular laser fluence to treat prolonged unresolved CSCR
Study: NCT01019668
Drug: verteporfin PDT, half-fluence
DrugBank: Verteporfin (DB00460)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: half the regular dose or half the regular laser fluence to treat prolonged unresolved CSCR
Study: NCT02996487
Drug: Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02776137
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel: 20mg/m2/w for 6 weeks